The crystal structure of SARS-CoV-2 3CL protease in complex with compound 3

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.

3CL-PRO,3CLp,Main protease,Mpro,Non-structural protein 5,nsp5,SARS coronavirus main proteinase

Severe acute respiratory syndrome coronavirus 2

0.1 M BIS-TRIS pH 6.5, 2.0 M Ammonium sulfate

HYDROGENS HAVE BEEN USED IF PRESENT IN THE INPUT U VALUES : REFINED INDIVIDUALLY

VIRAL PROTEIN-INHIBITO COMPLEX, Viral protein-inhibitor complex